Literatur
-
1
Borch-Johnsen K, Andersem P K, Deckert T.
The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.
Diabetologia.
1985;
28
590-596
-
2
Mogensen C E, Keane W F, Bennett P H, Jerums G, Parving H H, Passa P, Steffes M W, Striker G E, Viberti G C.
Prevention of diabetic renal disease with special reference to microalbuminuria.
Lancet.
1995;
346
1080-1084
-
3
American Diabetes Association .
Diabetic nephropathy.
Diabetes Care.
2002;
25
S85-S89
-
4
Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft (DDG).
Diabetes und Stoffwechsel.
2002;
11
1-40
-
5
Parving H H, Lehnert H, Bröchner-Mortensen J B, Gomis R, Andersen S, Arner P.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med.
2001;
345
870-878
-
6
Lewis E J, Hunsicker L G, Clarke W R, Berl T, Pohl M A, Lewis J B, Ritz E, Atkins R C, Rohde R, Raz I.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med.
2001;
345
851-860
-
7
Heinemann L, Hohmann A, Sawicki P T.
Proteinurie-Bestimmung.
Münch Med Wschr.
1990;
132
530-532
-
8
Sawicki P T, Heinemann L, Berger M.
Comparison of methods for determination of microalbuminuria in diabetic patients.
Diabetic Medicine.
1989;
6
412-415
-
9
Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R.
Patterns of renal injury in NIDDM patients with microalbuminuria.
Diabetologia.
1996;
39
1569-1576
-
10
Caramori M L, Fioretto P, Mauer M.
The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?.
Diabetes.
2000;
49
1399-1408
Prof. Dr. med. Dr. h. c. mult. E. Ritz
Medizinische Klinik - Sektion Nephrologie, Klinikum der Universität Heidelberg
Bergheimer Straße 56a
69115 Heidelberg
